ATM Protein Kinase Signaling, Type 2 Diabetes and Cardiovascular Disease

Cardiovascular Drugs and Therapy

Volumn 29, Issue 1, 2015, Pages 51-58

  Espach, Yolandi ^a   Lochner, Amanda ^a   Strijdom, Hans ^a   Huisamen, Barbara ^a,b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b MRC DDP   (South Africa)

Author keywords

Ataxia telangiectasia; Cardiovascular disease; Insulin resistance; Oxidative stress; Type 2 diabetes

Indexed keywords

ATM PROTEIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CYTOPLASM; DOUBLE STRANDED DNA BREAK; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; VASCULAR REMODELING; ANIMAL; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84925483499     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-015-6571-z     Document Type: Article

References (81)

1. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749–53.
2. Su Y, Swift M. Mortality rates among carriers of ataxia-telangiectasia mutant alleles. Ann Intern Med. 2000;133:770–8.
3. Rasio D, Negrini M, Croce CM. Genomic organization of the ATM locus involved in ataxia-telangiectasia. Cancer Res. 1995;55:6053–7.
4. Swift M, Morrel D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. 1986;39:573–83.
5. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499–506.
6. Yang DQ, Halaby M, Li Y, Hibmam JC, Burn P. Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration. Drug Discov Today. 2011;16:332–8.
7. Swift M, Chase C. Cancer and cardiac deaths in obligatory ataxia-telangiectasia heterozygotes. Lancet. 1983;321:1049–50.
8. Kim ST, Lim DS, Canman CE, Kastan MB. Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem. 1999;274:37538–43.
9. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science. 2010;330:517–21.
10. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J. 2003;22:5612–21.
11. Pellegrini M, Celeste A, Didilippantonio S, et al. Autophosphorylation at serine 1987 is dispensable for murine ATM activation in vivo. Nature. 2006;443:222–5.
12. Goodarzi AA, Jonnalagadda JC, Douglas P, et al. Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J. 2004;23:4451–61.
13. Sheeram S, Demidov ON, Hee WK, et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell. 2006;23:757–64.
14. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160–6.
15. Ditch S, Paull TT. The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem Sci. 2012;37:15–22.
16. Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2013;121:4036–45.
17. Semlitsch M, Shackelford RE, Zirkl S, Sattler W, Malle E. ATM protects against oxidative stress induced by oxidized low-density lipoprotein. DNA Repair. 2011;10:848–60.
18. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Moll Cell Biol. 2013;14:197–210.
19. Stagni V, Santini S, Barila D. Molecular bases of Ataxia Telangiectasia: one kinase multiple functions. In: Puiu M, editor. Genet Disord. InTech; 2013. doi:10.5772/54045.
20. Ambrose M, Goldstine JV, Gatti RA. Intrinsic mitochondrial dysfunctions in ATM-deficient lymphoblastoid cells. Hum Mol Genet. 2007;16:2154–64.
21. Valentin-Vega YA, MacLean KH, Tait-Mulder J, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012;199:1490–500.
22. Rosenberg P. Mitochondrial dysfunction and heart disease. Mitochondrion. 2004;4:621–8.
23. Ousset M, Bouquet F, Fallone F, et al. Loss of ATM positively regulates the expression of hypoxia inducible factor 1 (HIF-1) through oxidative stress. Cell Cycle. 2010;9:2814–22.
24. Watters DJ. Oxidative stress in ataxia telangiectasia. Redox Rep. 2003;8:23–9.
25. Arrigoni O, De Tullio MC. Ascorbic acid: much more than just an antioxidant. Biochim Biophys Acta. 2002;1569:1–9.
26. Buse MG, Robinson KA, Marshall BA, Mueckler M. Differential effects of GLUT1 or GLUT4 overexpression on hexosamine biosynthesis by muscles of transgenic mice. J Biol Chem. 1996;271:23197–202.
27. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549–80.
28. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation. 2005;112:1813–24.
29. van Weel V, Deckers MML, Grimbergen JM, et al. Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo. Circ Res. 2004;95:58–66.
30. Ordway GA, Garry DJ. Myoglobin: an essential hemoprotein in striated muscle. J Exp Biol. 2004;207:3441–6.
31. Schneider JG, Finck BN, Ren J, et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab. 2006;4:377–89.
32. Mead JR, Ramji DP. The pivotal role of lipoprotein lipase in atherosclerosis. Cardiovasc Res. 2002;55:261–9.
33. Mercer JR, Cheng KK, Figg N, et al. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res. 2010;107:1021–31.
34. Wu D, Yang H, Xiang W, et al. Heterozygous mutation of ataxia-telangiectasia mutated gene aggravates hypercholesterolemia in apoE-deficient mice. J Lipid Res. 2005;46:1380–7.
35. Armata HJ, Golebiowski D, Jung DY, Ko HJ, Kim JK, Sluss HK. Requirement of the ATM/p53 tumor suppressor pathway for glucose homeostasis. Mol Cell Biol. 2010;30:5787–94.
36. Razani B, Feng C, Semenkovich CF. p53 is required for chloroquine-induced atheroprotection but not insulin sensitization. J Lipid Res. 2010;51:1738–46.
37. Foster CR, Singh M, Subramanian V, Singh K. Ataxia telangiectasia mutated kinase plays a protective role in β-adrenergic receptor-stimulated cardiac myocyte apoptosis and myocardial remodeling. Mol Cell Biochem. 2011;353:13–22.
38. Krüger A, Ralser M. ATM is a redox sensor linking genome stability and carbon metabolism. Sci Signal. 2011;4:pe17.
39. Alexander A, Cai SL, Kim J, et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A. 2010;107:4153–8.
40. Cam H, Easton JB, High A, Houghton PJ. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell. 2010;40:509–20.
41. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008;22:239–51.
42. Viniegra JG, Martínez N, Modirassari P, et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem. 2005;280:4029–36.
43. Golding SE, Rosenberg E, Valerie N, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009;8:2894–902.
44. Jeong I, Patel AY, Zhang Z, et al. Role of ataxia telangiectasia mutated in insulin signaling of muscle-derived cell lines and mouse soleus. Acta Physiol. 2010;198:465–75.
45. Sano H, Kane S, Sano E, et al. Insulin-stimulated phosphorylation of a rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem. 2003;278:14599–602.
46. Consentino C, Grieco D, Constanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defense and DNA repair. EMBO J. 2011;30:546–55.
47. Katare R, Oikawa A, Cesselli D, et al. Boosting the pentose phosphate pathway restores cardiac progenitor cell availability in diabetes. Cardiovasc Res. 2013;97:55–6.
48. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res. 2000;87:1123–32.
49. Gray S, Kim JK. New insights into insulin resistance in the diabetic heart. Trends Endocrinol Metab. 2011;22:394–403.
50. Xie Z, He C, Zou MH. AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy. Autophagy. 2011;7:1254–5.
51. Das A, Durrant D, Koka S, Salloum FN, Xi L, Kukreja RC. mTOR inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression. J Biol Chem. 2013;289:4145–60.
52. Bloch-Damti A, Bashan N. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid Redox Signal. 2005;7:1553–67.
53. Evans JL, Maddux BA, Goldfin ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005;7:1040–52.
54. Le Guezennec X, Brichkina A, Huang YF, Kostromina E, Han W, Bulavin DV. Wip1-dependent regulation of autophagy, obesity, and atherosclerosis. Cell Metab. 2012;16:68–80.
55. Mercer JR, Yu E, Figg N, et al. The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+/−/ApoE−/− mice. Free Radic Biol Med. 2012;52:841–9.
56. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333–6.
57. Parthasarathy S, Steinberg D, Witzium JL. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med. 1992;43:219–25.
58. Nakagawa K, Taya Y, Tamai K, Yamaizumi M. Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks. Mol Cell Biol. 1999;19:2828–34.
59. Miles PD, Treuner K, Latronica M, Olefsky JM, Barlow C. Impaired insulin secretion in a mouse model of ataxia telangiectasia. Am J Physiol Endocrynol Metab. 2007;293:E70–4.
60. Halaby MJ, Hibma JC, He J, Yang DQ. ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells. Cell Signal. 2008;20:1555–63.
61. Yang DQ, Kastan MB. Participation of ATM in insulin signaling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol. 2000;2:893–8.
62. Ching JK, Luebbert SH, Collins RL, et al. Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signaling in skeletal muscle. Exp Physiol. 2013;98:526–35.
63. Peretz S, Jensen R, Baserga R, Glazer PM. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci U S A. 2001;98:1676–81.
64. Andrisse S, Patel GD, Chen JE, et al. ATM and GLUT1-S490 phosphorylation regulate GLUT1 mediated transport in skeletal muscle. PLoS One. 2013;8:e66027.
65. Zhou K, Bellenguez C, Spencer CCA, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes: the GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group and the Wellcome Trust Case Control Consortium 2. Nat Genet. 2011;43:117–20.
66. Birnbaum MJ, Shaw RJ. Drugs, diabetes and cancer: variation in a genomic region that contains the cancer-associated gene ATM affects a patient’s response to the diabetes drug metformin. Two experts discuss the implications for understanding diabetes and the link to cancer. Nature. 2011;470:338–9.
67. Barlow C, Hirotsune S, Paylor R, et al. ATM-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996;86:159–71.
68. Morrel D, Cromartie E, Swift M. Mortality and cancer incidence in 265 patients with ataxia-telangiectasia. J Natl Cancer Inst. 1986;77:89–92.
69. Shoelson SE. Banking on ATM as a new target in metabolic syndrome. Cell Metab. 2002;4:337–8.
70. Gertz EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J Clin Invest. 1988;82:2017–25.
71. Traegtmeyer H. Metabolism—the lost child of cardiology. J Am Coll Cardiol. 2000;36:1386–8.
72. Opie LH, Lopaschuk GD. Fuels: aerobic and anaerobic metabolism. In: Opie LH, editor. Heart physiology: from cell to circulation. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 306–54.
73. Eguchi K, Boden-Albala B, Jin Z, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol. 2008;101:1787–91.
74. Ghee M, Baker H, Miller JC, Ziff EB. AP-1, CREB and CBP transcription factors differentially regulate the tyrosine hydroxylase gene. Brain Res Mol Brain Res. 1998;55:101–14.
75. Gueven N, Keating K, Fukao T, et al. Site-directed mutagenesis of the ATM promoter: consequences for response to proliferation and ionizing radiation. Genes Chromosome Cancer. 2003;38:157–67.
76. Shizukuda Y, Buttrick PM, Geenen DL, Borczuk AC, Kitsis RN, Sonnenblick EH. β-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol. 1998;275:H961–8.
77. Foster CR, Zha Q, Daniel LL, Singh M, Singh K. Lack of ataxia telangiectasia mutated kinase induces structural and functional changes in the heart: role in β-adrenergic receptor-stimulated apoptosis. Exp Physiol. 2012;97:506–15.
78. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520–30.
79. Foster CR, Daniel LL, Daniels CR, Dalal S, Singh M, Singh K. Deficiency of ataxia telangiectasia mutated kinase modulates cardiac remodeling following myocardial infarction: involvement in fibrosis and apoptosis. PLoS One. 2013;8:e83513.
80. Vecchio D, Frosina G. Targeting the ataxia telangiectasia mutated protein in cancer therapy. Curr Drug Targets. 2014;PMID 25382204.
81. Lee JH, Guo Z, Myler LR, Zheng S, Paull TT. Direct activation of ATM by resveratrol under oxidizing conditions. PLoS One. 2014;9:e97969.